• Publications
  • Influence
A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.
A recombinant vaccine based on fusion of the circumsporozoite protein and HBsAg plus a potent adjuvant can protect against experimental challenge with P. falciparum malaria. Expand
Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.
While antibody responses were generally poor, cellular immune responses were detected in >90% of the volunteers and there was a significant delay in time to parasite patency in the groups of volunteers who received either the low or high dose of vaccine compared with control volunteers. Expand
Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine.
Further optimization in vaccine composition and/or immunization schedule will be required to induce longer-lasting protective immunity in malaria sporozoite vaccine candidate RTS,S. Expand
Trypanosoma congolense. I. Clinical observations of experimentally infected cattle.
Abstract The course of disease was studied in 8 cattle infected with Trypanosoma congolense . Although the onset of patency was dependent on the numbers of infecting organisms, the duration of theExpand
Trypanosoma congolense: natural and acquired resistance in the bovine.
Animals infected with Trypanosoma congolense showed some resistance to infection and young animals which needed no treatment to survive were refractive to challenge for at least 1 year after their last patent parasitemia and older animals which required treatment to surviving were challenged at intervals after therapy. Expand
Experimental infection of cattle with Trypanosoma brucei rhodesiense.
Infection of cattle with various stocks of Trypanosoma brucei rhodesiense indicated that 49% developed a fatal CNS disease comparable to that found in man. Duration of disease ranged from 85 to 1613Expand
Presenting features of Rhodesian sleeping sickness patients in the Lambwe Valley, Kenya.
During a recent outbreak of Rhodesian sleeping sickness in the Lambwe Valley no asymptomatic Rhodesian sleeping sickness patients were found although 54% of the primary patients had mild symptoms andExpand
A history of sleeping sickness in Kenya.
The Rhodesian form of sleeping sickness appeared in the Lambwe Valley, South Nyanza, in about 1959, and despite attempts to eradicate this disease it still persists as the only remaining endemic area in Kenya at this time. Expand
NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria
It is demonstrated that NYVAC-Pf7 is an appropriate candidate vaccine for further evaluation in human clinical trials and genotypic and phenotypic stability of the recombinant virus was demonstrated. Expand
Plasmodium vivax infections in U.S. Army troops: failure of primaquine to prevent relapse in studies from Somalia.
The apparent ineffectiveness of primaquine therapy in preventing relapses suggests the presence ofPrimaquine-resistant P. vivax strains in Somalia. Expand